University of Huddersfield Repository


Hypoxia Sensitive Metal β-Ketoiminate Complexes Showing Induced Single Strand DNA Breaks and Cancer Cell Death by Apoptosis

Original Citation


This version is available at http://eprints.hud.ac.uk/id/eprint/24441/

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

http://eprints.hud.ac.uk/
Hypoxia Sensitive Metal $\beta$-Ketoiminato Complexes Showing Induced Single Strand DNA Breaks and Cancer Cell Death by Apoptosis


School of Chemistry, University of Leeds, Leeds, UK, LS2 9JT. Email: p.c.mcgowan@leeds.ac.uk, Tel: +44(o)113 3436404

Institute of Cancer Therapeutics, University of Bradford, Bradford, UK, BD7 1DP

Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH

ABSTRACT: A series of ruthenium and iridium complexes have been synthesised and characterised with 20 novel crystal structures discussed. The library of $\beta$-ketoiminato complexes has been shown to be active against MCF-7 (human breast carcinoma), HT-29 (human colon carcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant human ovarian carcinoma) cell lines, with selected complexes being more than three times as active as cisplatin against the A2780cis cell line. Complexes have also been shown to be highly active under hypoxic conditions, with the activities of some complexes increasing with a decrease in O$_2$ concentration. The enzyme thioredoxin reductase is over-expressed in cancer cells and complexes reported herein have the advantage of inhibiting this enzyme, with IC$_{50}$ values measured in the nanomolar range. The anti-cancer activity of these complexes was further investigated to determine whether activity is due to effects on cellular growth or cell survival. The complexes were found to induce significant cancer cell death by apoptosis with levels induced correlating closely with activity in chemosensitivity studies. As a possible cause of cell death, the ability of the complexes to induce damage to cellular DNA was also assessed. The complexes failed to induce double strand DNA break or DNA crosslinking but induced significant levels of single DNA strand breaks indicating a different mechanism of action to cisplatin.

Introduction

Ruthenium has become one of the most popular metals used in drug development due to the metal's easily accessible oxidation states, stability in air and the relative ease of synthesis of organometallic and coordination complexes. Most importantly ruthenium is thought to have slow in vivo ligand exchange and higher selectively towards cancer cells leading to lower toxicity.$^{1-4}$ The discovery of organometallic ruthenium complexes first began with the library of [(η$^6$-arene)Ru(II)(en)X]+ (X = halide, en = ethylenediamine) complexes synthesised by Sheldrick et al.$^{5-7}$ The effect of the ligand was later explored by Sadler et al. substituting the neutral (N,N) ethylenediamine ligand for an anionic (O,O) $\beta$-diketonato ligand, showing a significant increase in cytotoxicity of the complexes.$^8$ In collaboration with Sadler, McGowan et al. first synthesised picolinamide Ru(II) and Os(II) arene complexes due to their relevance to previously reported metal ion-peptide chemistry$^9-12$ and the possibility of different binding modes, through either a monoanionic (N,N) or a neutral (N,O) form. Studies showed that the more cytotoxic (N,N) complexes undergo rapid hydrolysis and bind preferentially to guanine, whereas switching the binding mode to (N,O) slows the rate of hydrolysis and switches off the activity.$^{12,13}$ McGowan et al. also synthesised ruthenium and iridium complexes incorporating either a picolinamide (N,N), $\beta$-ketoiminato (N,O) or a naphthoquinone (O,O) ligand and compared the effects of these substitutions upon cytotoxicity. The IC$_{50}$ values obtained for both HT-29 and MCF-7 cancer cell lines suggest that the binding mode is a critical determinant of complex activity. The lowest IC$_{50}$ values were observed for the $\beta$-ketoiminato (N,O) complexes for both ruthenium and iridium and anti-cancer activity followed the general trend (N,O) > (O,O) > (N,N).$^{14}$

Herein we report the synthesis and characterisation of a new series of (N,O) and (O,O) complexes and analysis of their biological effects, gaining an understanding of their biological mechanisms. We report on the cytotoxic potential of our library of novel complexes, with potent cancer cell cytotoxicity observed, particular against the cisplatin resistant ovarian cell line (A2780cis). As many tumours have a significant hypoxic fraction and hypoxic tumour cells are typically resistant to standard chemotherapy and radiotherapy,$^{15-17}$ IC$_{50}$ values were also obtained for cells grown under low oxygen conditions. This enabled us to evaluate the potential of these complexes for targeting tumour cells that reside in a hypoxic microenvironment and which are a common cause of chemoresistance and tumour recurrence. Further
mechanistic studies have been undertaken to assess whether the anti-cancer activity of the novel complexes is due to effects upon cellular growth and proliferation or due to effects upon cell survival. The complexes were tested against HT-29 and A2780 cells at varying concentrations and effects on cell phenotype determined. Cell images were recorded under phase contrast microscopy at various time-points and levels of cell death by apoptosis and necrosis were quantified. Studies have also been carried out to assess the possibility of thioredoxin reductase (Trx-R) inhibition, using UV/vis spectroscopy to monitor Trx-R activity following incubation of Trx-R enzyme with varying concentrations of our complexes. Finally, more detailed mechanistic studies have been undertaken to assess equivalent of either $[p$-cymRuCl$_2$]$_2$ (Scheme 2a) or $[Cp^*$IrCl$_2$]$_2$ (Scheme 2b) was stirred with two equivalents of the functionalised ligand and two equivalents of triethylamine in dichloromethane. Complexes 1-18 were isolated as analytically pure complexes from methanolic solutions in yields 46-71% and have been characterised by $^1$H NMR spectroscopy, $^{13}$C($^1$H) NMR spectroscopy, mass spectrometry and microanalysis. Complexes 2, 4-14 and 17-18 were also characterised by single crystal X-ray crystallography.

Results and discussion

Synthesis and Characterisation

The $\beta$-ketoenamine ligands $L_2$-$L_{13}$ were synthesised according to Scheme 1. Ligand $L_{14}$ has previously been reported by Roshchupkina et al. The corresponding $\beta$-diketonate ligands were prepared and dissolved with stirring in toluene, followed by addition of excess aniline and hydrochloric acid. Ligands were obtained as analytically pure compounds from solutions of hot ethanol in yields of 38-88% and characterised by $^1$H NMR spectroscopy, $^{13}$C($^1$H) NMR spectroscopy, mass spectrometry and microanalysis. Ligands $L_3$-$L_6$, 8 and 11 were also characterised by single crystal X-ray crystallography.

The half-sandwich $\beta$-ketoiminato and $\beta$-diketonato complexes were synthesised according to Scheme 2. One
Figure 2 Molecular structures for ligands L3-6, 8 and 11. Hydrogen atoms omitted for clarity. Displacement ellipsoids are at the 50% probability level.

Figure 3a Molecular structures for complexes 2 and 4-14. Hydrogen atoms omitted for clarity. Displacement ellipsoids are at the 50% probability level.
X-ray crystallographic data has been analysed for complexes 2, 4-14, 17 and 18, and all single crystals were obtained using slow evaporation from a methanolic solution, appearing as orange/red (ruthenium) or yellow (iridium) single crystals. Solutions were performed in a monoclinic Cc (4 and 7) or P2₁/c (14), triclinic P 1 (2, 5, 6, 8-13 and 17), or orthorhombic P2₁2₁2₁ (18) space groups. All of the angles around the metal centre show the geometry expected for pseudo octahedral compounds which is common for half-sandwich “piano-stool” structures (see Tables S3-4, SI). The angles between the metal and bidentate ligands are in the range 83-90°, with the remaining three coordination sites occupied by the p-cymene or Cp* ligand and the angles observed for their centroids to the chloride or bidentate ligand ranges between 124-133°. Molecular structures for complexes 2, 4-14, 17 and 18 are shown in Figure 3a and 3b, with displacement ellipsoids placed at the 50% probability level and hydrogen atoms omitted for clarity.

![Molecular structures for iridium(III) complexes 17 and 18. Hydrogen atoms omitted for clarity. Displacement ellipsoids are at the 50% probability level.](image)

![Intramolecular interactions for a) complex 1, b) complex 2 and c) complex 8.](image)

The 'H NMR spectra for the ruthenium β-ketoiminato complexes show a significant upfield shift of 1.3-1.6 ppm for one of the p-cymene hydrogens. Analysis of the X-ray structure shows one of these hydrogens undergoes intramolecular T-stacking interactions with the aniline ring at D...A distances between 3.33-3.62 Å (Figure 4). This type of interaction has previously been reported with a library of complexes of the type [areneRuCl(XY)] (where XY = N,O ligand) synthesised by Dyson et al., in which it was noted these complexes can exist as two conformers, with variable temperature NMR studies showing the presence of both conformers at lower temperatures. Interactions are also seen between the p-cymene hydrogen and the ancillary chloride ligand with D...A distances of 3.37-3.34Å (Figure 4).

**Cell Line Chemosensitivity Studies**

In order to gain information about the structure-activity relationships of the different complexes, chemosensitivity studies were performed and IC₅₀ values were determined for HT-29, MCF-7, A2780, and A2780cis cancer cell lines exposed to each of complexes 1-18 or to cisplatin (Table 1 and Figure S2). The results show that the ruthenium β-ketoiminato complexes are all cytotoxic towards the cancer cell lines tested, with particular activity against both A2780 and A2780cis cell lines. Complex 1 was the most active complex against all four cancer cell lines, with the lowest IC₅₀ value for MCF-7 of 1.9 ± 0.1 µM (cisplatin 0.98 ± 0.09 µM), and significant activity against the cisplatin-resistance cell line A2780cis in which it was ~3-fold more active than cisplatin (3.13 ± 0.09 µM versus 10.5 ± 0.2 µM). This suggests that the mechanism of action and resistance of these complexes is different from cisplatin and raises the possibility that some of these complexes could potentially be used to treat cancer which has become resistant to cisplatin. This library shows that complexes 1-7, which have electron withdrawing substituents, are the most potent against all tested cell lines. While introduction of electron donating groups or sterically bulky groups usually leads to a slight decrease in activity (complexes 11, 12, 14, 16 and 17). However, on comparison of substituents in the para position, when a methyl substituent was introduced (complex 11), anti-cancer activity increased in comparison to the para electron withdrawing substituents and this complex was the most active para complex against MCF-7 cells, with an IC₅₀ value of 2.1 ± 0.1 µM (cisplatin 1.07 ± 0.10 µM). Control experiments were also performed to investigate whether the ligands alone possess any cytotoxic activity in vitro. Ligands L2, 4 and L7 were tested against HT-29 cancer cells and all were considered to be inactive with IC₅₀ values greater than the tested threshold (>250 µM) (Table 1).
Table 1 IC₅₀ values for cisplatin and complexes 1-18 against HT-29, MCF-7, A2780, A2780cis and ARPE-19 cell lines. The values in parenthesis represent the IC₅₀ values for the ARPE-19 cells divided by IC₅₀ values for individual cancer cells (values greater than 1 indicate selectivity for cancer cells over the non-cancer ARPE-19 cells).

<table>
<thead>
<tr>
<th>Complex</th>
<th>HT-29 IC₅₀ (µM) ± SD</th>
<th>MCF-7 IC₅₀ (µM) ± SD</th>
<th>A2780 IC₅₀ (µM) ± SD</th>
<th>A2780cis IC₅₀ (µM) ± SD</th>
<th>ARPE-19 IC₅₀ (µM) ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>2.40 ± 0.10 (2.49)</td>
<td>1.09 ± 0.08 (5.47)</td>
<td>0.94 ± 0.04 (3.65)</td>
<td>10.50 ± 0.20 (0.57)</td>
<td>5.97 ± 0.95</td>
</tr>
<tr>
<td>1</td>
<td>3.50 ± 0.30 (1.28)</td>
<td>1.90 ± 0.10 (2.36)</td>
<td>2.60 ± 0.08 (1.72)</td>
<td>3.13 ± 0.09 (1.43)</td>
<td>4.48 ± 0.07</td>
</tr>
<tr>
<td>2</td>
<td>10.50 ± 0.40</td>
<td>5.07 ± 0.09</td>
<td>2.80 ± 0.10</td>
<td>3.47 ± 0.07</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5.40 ± 0.09</td>
<td>3.00 ± 0.20</td>
<td>1.70 ± 0.10</td>
<td>3.80 ± 0.10</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4.30 ± 0.50</td>
<td>3.22 ± 0.09</td>
<td>2.35 ± 0.04</td>
<td>5.59 ± 0.05</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>11.40 ± 0.60</td>
<td>3.50 ± 0.20</td>
<td>2.50 ± 0.10</td>
<td>6.40 ± 0.10</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>12.60 ± 0.02</td>
<td>3.27 ± 0.08</td>
<td>2.86 ± 0.04</td>
<td>11.50 ± 0.30</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>6.10 ± 0.30 (1.27)</td>
<td>3.55 ± 0.09 (2.18)</td>
<td>2.5 ± 0.2 (3.10)</td>
<td>3.69 ± 0.09 (2.10)</td>
<td>7.76 ± 0.07</td>
</tr>
<tr>
<td>8</td>
<td>10.30 ± 0.60 (1.48)</td>
<td>6.20 ± 0.20 (2.47)</td>
<td>2.3 ± 0.2 (6.67)</td>
<td>7.00 ± 0.04 (2.19)</td>
<td>15.33 ± 0.41</td>
</tr>
<tr>
<td>9</td>
<td>11.80 ± 0.80 (1.02)</td>
<td>-</td>
<td>-</td>
<td>12.00 ± 1.47</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>12.80 ± 0.50</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>10.21 ± 0.09 (0.89)</td>
<td>2.90 ± 0.10 (3.16)</td>
<td>2.87 ± 0.05 (3.19)</td>
<td>9.1 ± 0.1 (1.01)</td>
<td>9.17 ± 2.36</td>
</tr>
<tr>
<td>12</td>
<td>22.00 ± 2.00 (0.32)</td>
<td>13.00 ± 0.20 (0.55)</td>
<td>-</td>
<td>-</td>
<td>7.17 ± 0.93</td>
</tr>
<tr>
<td>13</td>
<td>6.30 ± 0.30 (0.57)</td>
<td>7.20 ± 0.20 (0.50)</td>
<td>1.90 ± 0.10 (1.91)</td>
<td>3.80 ± 0.09 (0.95)</td>
<td>3.62 ± 0.03</td>
</tr>
<tr>
<td>14</td>
<td>53.00 ± 1.00 (0.60)</td>
<td>-</td>
<td>56.00 ± 2.00 (0.57)</td>
<td>-</td>
<td>32.03 ± 9.23</td>
</tr>
<tr>
<td>15</td>
<td>18.00 ± 2.00 (2.86)</td>
<td>18.40 ± 0.80 (2.80)</td>
<td>19.40 ± 0.80 (2.66)</td>
<td>24.30 ± 0.50 (2.12)</td>
<td>51.55 ± 5.14</td>
</tr>
<tr>
<td>16</td>
<td>5.10 ± 0.30</td>
<td>3.40 ± 0.20</td>
<td>5.70 ± 0.10</td>
<td>5.80 ± 0.50</td>
<td>-</td>
</tr>
<tr>
<td>17</td>
<td>83.00 ± 3.00</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18</td>
<td>93.00 ± 7.00 (&gt;2)</td>
<td>51.00 ± 4.00 (&gt;2)</td>
<td>35.00 ± 1.00 (&gt;2.9)</td>
<td>51.00 ± 1.00 (&gt;2)</td>
<td>100</td>
</tr>
<tr>
<td>L2</td>
<td>&gt; 250</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>L3</td>
<td>&gt; 250</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>L4</td>
<td>&gt; 250</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>L7</td>
<td>&gt; 250</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Selectivity for cancer cells

Comparing the response of tumour cell lines to non-cancer ARPE-19 cells provides a preliminary indication of selectivity. Whilst compounds 9, 12, 13 and 14 show no selectivity towards cancer cells (ratio of IC₅₀ values in ARPE-19 cells to cancer cells ≤ 1), compounds 1, 7, 8, 11 and 15 showed evidence of selectivity to certain cancer cells (Table 1). The magnitude of the selectivity observed in the test compound series was comparable to that obtained for cisplatin with ratio’s of IC₅₀ values in ARPE-19 to cancer cells ranging from 6.67 to 1.27 for test compounds and 6.35 to 0.57 for cisplatin (Table 1). Compound 8 in particular demonstrated good selectivity against all the cancer cell lines tested with selectivity ranging from 6.67 to 1.48 fold increased chemosensitivity towards cancer cells compared to ARPE-19 non-cancer cells (A2780: 6.67; A2780cis: 2.19; MCF7: 2.47; HT29: 1.48; Table 1). These results provide a preliminary indication that some compounds are selectively toxic to cancer cells.

Due to the high in vitro activity for complex 1, complexes 15, 16 and 18 were synthesised in order to make comparisons between the biological mechanisms on changing both the ligands and metal centres. Complexes 1 and 16 incorporate a 3-fluoro-β-ketoiminato (N,O) ligand, whilst complex 15 and 18 incorporate the 3-fluoro-β-diketonato (O,O) ligand, on ruthenium and iridium respectively. On comparison of complex 1 (N,O) and the β-diketonato complex 15 (O,O), changing the binding mode and hence elimination of the aniline ring, dramatically decreased cell line cytotoxicity, with complex 15 being up to 9-fold less active than its (N,O) analogue. Also on comparison of two (N,O) complexes 1 and 14, substituting the aniline ring for NH (14) showed a 21-fold decrease in activity when compared to 1. The iridium Cp⁺ β-ketoiminato complex 16 was synthesised and compared to the iridium β-diketonato analogue 18. As seen with the ruthenium complexes, the (O,O) ligand had up to an 18-fold decrease in activity against HT-29. Again on comparison of two (N,O) complexes 16 and 17, the aniline was substituted for NH (17) and the activity decreased by 16-fold when compared to complex 16.
These results indicate that for the complexes tested, the aniline ring is critical for high in vitro anti-cancer activity and on elimination of this ring complex activity is substantially diminished, proving that the design of the ligand is essential in drug development.

**Influence of Hypoxia**

For many solid tumours, a significant proportion of the tumour cells are under conditions of limiting oxygen or hypoxia and the cellular environment is reducing. The hypoxia-inducible factor-1 (HIF-1) is central to the cell’s response to hypoxia and under hypoxic conditions it activates a transcriptional program that helps tumour cell adaptation and survival under low oxygen conditions. Transition metals have the potential to be reduced under hypoxic conditions and these changes in oxidation states could lead to changes in structure, binding mode, cellular drug uptake and metabolism as well cellular mechanism of action and the effectiveness of this. Using complexes 1, 15, 16 and 18, 5-day in vitro MTT studies were conducted under hypoxic conditions at both 0.1% and 1.0% O₂ against HT-29 cells, in order to assess the impact of oxygen concentration upon chemosensitivity (Figure 5). The complexes were compared to the hypoxia-activated pro-drug tirapazamine and to cisplatin. Results show that reducing the O₂ concentration gave a general decrease in cytotoxicity for the (O,O) complexes 15 and 18, with the reduction in activity more pronounced at 0.1% O₂. The iridium (N,O) complex 16 is active under hypoxic conditions albeit less so than under normoxia (21% O₂), with an IC₅₀ value of 20 ± 2 µM at 0.1% O₂. Complex 1 shows a small decrease in its activity in response to low oxygen conditions, but remains highly active even at 0.1% O₂ concentration, confirming its potential as a drug candidate for targeting both normoxic and hypoxic cancer cells.

**Figure 5 Hypoxic values for complexes 1, 15, 16 and 18 against HT-29**

The preliminary in vitro screening of the complexes indicated that the complexes with a substituents in the para position of the β-ketoiminato ligand were highly potent against the cell lines tested (Table 1), and these complexes made good candidates for hypoxia studies. Therefore, in order to further probe the effects of hypoxia on these complexes a range of para substituted complexes (2, 3, 8, 9 and 11) were tested under hypoxic conditions (Figure 6). Complexes tested at 0.1% O₂ were still active under hypoxic conditions and for all para complexes tested, the anti-cancer activity actually increased at 0.1% O₂, indicating that these complexes are hypoxia sensitive. The most noticeable results were seen for complexes 2 and 8, which both have nearly 2-fold lower IC₅₀ values under hypoxic conditions. This indicates the potential of these complexes or similar derivatives as hypoxia targeting anti-cancer agents.

**Figure 6 Hypoxic results for complexes 2, 3, 8, 9 and 11 against HT-29**

**Inhibition of thioredoxin reductase activity**

The MTT assay is the gold standard for in vitro chemosensitivity studies and IC₅₀ determination but it does not provide any information as to how the drugs may possess their anti-cancer effects. To try and gain some preliminary insight into this, additional assays were conducted for possible effects of the drugs upon, a) thioredoxin reductase activity, b) induction of DNA damage, and, c) induction of cell death. The biological effects of the thioredoxin reductase 1 (Trx-R) system have been shown to contribute to tumour growth and progression. Over-expression of thioredoxin reductase 1 has been reported in several tumour types and the enzyme is an important therapeutic target in anti-cancer drug development. In order to investigate the mode of action of our novel complexes, the inhibition of Trx-R activity by complexes 1, 15, 16 and 18 was investigated. Previously, a range of iridium picolinamide complexes were found to inhibit Trx-R, with IC₅₀ values in the nanomolar range. However, the analogous ruthenium picolinamide complexes failed to show any enzyme inhibition. In this work, both ruthenium and iridium β-ketoiminato complexes (1 and 16) were found to be potent Trx-R inhibitors with IC₅₀ values in the nanomolar range. The β-diketonato complexes 15 and 18 are less active against Trx-R, but still have IC₅₀ values in the low micromolar range (see Figure S3). Trx-R inhibition may thus contribute to the anti-cancer activity of some of our novel complexes; although it is likely that other mechanisms may also be important.

**Induction of cancer cell death by apoptosis**

The IC₅₀ values determined by chemosensitivity studies using the MTT assay indicate the concentration of drug required for a 50% reduction in viable cell number. Whilst this provides invaluable information on the
activity of the drug against the cell line testing, the MTT assay does not distinguish between effects on cell proliferation and effects on cell survival. Thus, the observed activity of our novel complexes towards the four cancer cell lines could be caused by induction of cell growth arrest or the complexes may actually cause cell death. Cell images under phase contrast microscopy at various time-points after complex addition suggested induction of cell death rather than growth arrest. Using flow cytometry and annexin V/propidium iodide staining the percentage of live cells, early apoptotic cells and late apoptotic/necrotic cells were quantified following incubation of HT-29 or A2780 cells with 10 or 20µM of complexes 1, 15, 16 and 18 for 48 hours (Figure 7 and Table S8).

The β-ketoiminato complexes 1 and 16, which were amongst the most active complexes in the MTT chemosensitivity studies, induced significant levels of apoptotic cell death in both the HT29 (Figure 7a) and A2780 (Figure 7b) cancer cell lines in a dose-responsive manner. A 48 hour exposure of HT29 cells to 10 µM of the β-ketoiminate ruthenium complex 1 resulted in ~50% early apoptotic cells and ~40% late apoptotic/necrotic cells. A 20 µM dose resulted in over 70% of cells staining positive for late apoptosis/necrosis. 20 µM of the active β-ketoiminato iridium complex 16 also induced significant apoptosis, with 31.7% early apoptotic cells and 49.9% late apoptotic or necrotic cells following 48 hour exposure. In contrast, the ruthenium and iridium β-diketonato analogues 15 and 18 respectively, induced only very low levels of apoptosis/necrosis, consistent with their much higher IC50 values and lower activity in the chemosensitivity studies (see Table 1). Although levels of apoptosis and necrosis were higher than background levels obtained with the controls and higher levels were induced by 20 µM of drug than with 10 µM, even at the highest drug concentration of 20 µM the majority of cells (>84%) were still viable. These observations indicate a clear correlation between IC50 value and levels of apoptosis/necrosis induced.

A very similar pattern was also observed for A2780 cells demonstrating that for these two cancer cell lines at least, the ruthenium and iridium β-ketoiminato complexes 1 and 16 induce high levels of cancer cell death by apoptosis, in a dose-dependent manner. This is consistent with their low IC50 values and indicates a mechanism by which they are able to exert their in vitro anti-cancer activity which merits further future investigation.

**Analysis of cellular DNA damage by the comet assay**

Accumulation of cellular DNA damage ultimately leads to the demise of the cell by apoptosis (programmed cell death). As a potential cause of the apoptotic phenotype induced by complexes 1 and 16 (see Figure 7) we therefore determined whether the complexes induce any form of cellular DNA damage. Complexes 1, 15, 16, and 18 and cisplatin were tested for induction of double strand DNA breakage (DSB), single strand DNA breakage (SSB) and DNA cross-linking. Increasing concentrations of the complexes or of cisplatin were incubated with HT-29 cells for 24 hours before harvesting and quantification of the levels of different types of DNA damage in single cells using the either the alkaline or neutral comet assay (see SI). None of the complexes induced significant levels of double strand DNA breaks at any of the concentrations tested (Figure 8a) and this was also the case for cisplatin, as previously reported.34-35

![Figure 7](image)

**Figure 7 Apoptosis results for complexes 1, 15, 16 and 18 against HT-29**

![Figure 8](image)

**Figure 8b** Apoptosis results for complexes 1, 15, 16 and 18 against A2780

The complexes also failed to induce DNA cross-linking (see Figure S4-S6), whereas cisplatin induced significant DNA cross-linking, consistent with its mechanism of action.36 Importantly however, the ruthenium β-ketoiminato (N,O) complex 1 induced high levels of single-strand DNA breaks with levels of SSB damage increasing in a dose-dependent manner with increasing concentrations of complex 1 (Figure 8b). In contrast the analogous ruthenium β-diketonato (O,O) complex 15 caused no single strand DNA breakage (Figure 9) indicating the importance of the binding ligand and consistent with the much lower activity of complex 15 compared to complex 1 in both chemosensitivity studies (Table 1) and cell viability analyses (Figure 7).

![Image](image)
Double Strand Breakage (DSB)

Single strand Breakage (SSB)

**Figure 8** DSB and SSB results for complexes 1, 15, 16 and 18 against HT-29

The iridium complexes showed the same general trend, with the β-ketoiminato (N,O) complex 16 also inducing SSB formation similar to its ruthenium analogue (complex 1) although the extent of DNA damage was less. The iridium β-diketonato (O,O) complex 18, like its ruthenium β-diketonato counterpart (complex 15), induced no SSB formation. Thus, for both ruthenium and iridium complexes, the (N,O) ligand appears to be important for complex induction of cellular single strand DNA breaks. Whilst other mechanisms may also be involved, the induction of SSB damage provides a possible cause of the apoptotic phenotype induced by complexes 1 and 16.

The observation that complexes 1 and 16 induce significant single strand DNA breaks in a dose-dependent manner but few double strand breaks or DNA cross-links (Figures 8, 9 and Figures S4-S6) suggests a different mechanism of action to cisplatin which primarily induces DNA cross-linking. It is also informative with respect to possible combinational chemotherapeutic approaches, suggesting that complexes 1 and 16 may be particularly effective if used in combination with inhibitors of single strand break repair, such as PARP inhibitors. Another approach that may be effective is in combination with DNA damaging chemotherapeutic agents that work by a different mechanism, for example by inducing DSBs, such as doxorubicin or etoposide. Future studies will investigate how the compounds might induce SSBs, for example by inhibition of topoisomerase 1, and will include combinatorial studies with other classes of DNA damaging chemotherapeutic agents for synergistic effects.

Overall, our results identify the ruthenium and iridium complexes with the β-ketoiminato (N,O) ligand (complexes 1 and 16) as the most potent and promising of the novel complexes and these are good candidates for future investigation including more detailed mechanistic studies, in vitro and in vivo ADME studies and analysis of cancer selectivity in vivo.

**Conclusions**

From the library of novel ruthenium and iridium complexes tested in this study, our results identify the complexes with a β-ketoiminato ligand as the most active. IC_{50} values varied depending on the complex and cell line.
but were typically below 15 µM for all four cancer cell lines tested (HT-29, MCF-7, A2780, A2780cis). Importantly, almost all of the β-ketoiminoato complexes were slightly more active than cisplatin against the cisplatin-resistant cell line A2780cis. With complex 1 showing a 3-fold increase in activity when compared to cisplatin. Complexes with the aniline ring removed were investigated the inhibition of thioredoxin reductase, with showing a 3 -fold increase in activity when compared to cisplatin-resistant cell line A2780cis. The complexes were tested under hypoxic (1% O₂) or severely hypoxic conditions. Many of the β-ketoiminoato complexes were more active under hypoxia indicating that these β-ketoiminoato complexes are hypoxia-sensitive. As a possible mechanism of action we investigated the inhibition of thioredoxin reductase, with results showing inhibition of this enzyme, with IC₅₀ values in the nanomolar range. Further mechanistic investigation showed that the β-ketoiminoato complexes fail to induce growth arrest but i) induce significant cancer cell death by apoptosis and, ii) single strand DNA breakage - indicating a different mechanism of action to cisplatin. The unexpected enhanced activity of many of the β-ketoiminoato complexes under hypoxic conditions warrants further investigation but is encouraging in the search for novel anti-cancer agents that are capable of targeting both normoxic and hypoxic cells of a solid tumour.

**X-ray Crystallography**

A suitable single crystal was selected and immersed in an inert oil. The crystal was then mounted on a goniometer head on a Bruker X8 Apex diffractometer using graphite monochromated Mo-Kα radiation (λ = 0.71073 Å) or an Agilent SuperNova diffractometer using mirror monochromated Mo-Kα radiation (λ = 0.71073 Å), using 0.9° φ-rotation frames. The crystal was cooled to between 100-173 K by an Oxford Cryostream low temperature device. The full data sets were recorded and the images processed using DENZO and SCALEPACK programs or CrysAlis Pro software. Structure solution by direct methods was achieved through the use of SHELXS programs, and the structural model refined by full matrix least squares on F² using SHELX97. Unless otherwise stated, hydrogen atoms were placed using idealised geometrical positions (with free rotation for methyl groups), allowed to move in a "riding model" along with the atoms to which they were attached, and refined isotropically.

**Synthesis**

**Ligands L2-L12**

All ligands were synthesised by dissolving the corresponding functionalised β-diketonato (0.5 g) in toluene (10 ml), followed by addition of aniline (1 ml) and HCl (0.5 ml). The mixture was stirred overnight and the precipitate filtered under reduced pressure. The solvent was removed from the filtrate and then recrystallised from hot ethanol to yield analytically pure compounds.

**Ligand L2 (0.63 g, 2.5 mmol, 87%)**

1H NMR (CDCl₃, 300 MHz, 300 K) δ 13.05 (s, 1H, NH), 7.94 (v. dd, 2H, CH, J(H-H) = 9.2 Hz and J(H-19F) = 2.3 Hz), 7.39 (br. t, 2H, CH, J(H-H) = 7.9 Hz), 7.24 (br. t, 1H, CH, J(H-H) = 7.6 Hz), 7.19 (br. d, 2H, CH, J(H-H) = 7.2 Hz), 7.11 (v. t, 2H, CH, J(H-H) = 8.7 Hz and J(H-19F) = 1.9 Hz), 5.85 (s, 1H, methine CH, H₃), 2.15 (s, 1H, aliphatic CH), 3C{1H} NMR (CDCl₃, 75MHz, 300K) δ 187.2 (s, 1H), 75.1 (d, Q C-F, J(C-C) = 249.7 Hz), 162.4 (Q), 138.5 (Q), 129.3 (d, 2 x CH, J(C-19F) = 8.7 Hz), 129.2 (2 x CH), 125.9 (CH), 124.8 (2 x CH), 115.2 (d, 2 x CH, J(C-C) = 21.0 Hz), 93.8 (methylene CH), 20.4 (aliphatic CH) Analysis Calculated for C₆H₅FNO: C 74.35, H 5.40, N 8.71; Found C 74.40, H 5.45, N 8.69.

**Ligand L3 (0.35 g, 1.0 mmol, 51%)**

1H NMR (CDCl₃, 300 MHz, 300 K) δ 13.12 (s, 1H, NH), 7.90 (d, 2H, CH, J(H-H) = 8.5 Hz), 7.44 (d, 2H, CH, J(H-H) = 8.5 Hz)
Ligand L4 (0.58 g, 2.0 mmol, 88%)

1H NMR (CDCl3, 500 MHz, 300 K) δ 12.86 (s, iH, NH), 7.43 (m, iH, CH), 7.33 (br. t, 2H, CH, 1JH-H = 7.5 Hz), 7.42 (br. s, iH, CH), 7.17-7.16 (m, 2H, CH), 7.13 (d, 2H, CH, 1JH-H = 7.5 Hz), 5.43 (s, iH, methine CH), 2.03 (s, 3H, aliphatic CH3) 13C{1H} NMR (CDCl3, 75 MHz, 300 K) δ 187.8 (Q), 137.4 (Q), 129.7 (2 x CH), 127.4 (2 x CH), 126.7 (CH), 125.4 (2 x CH), 98.5 (methine CH), 20.8 (aliphatic CH3) Analysis Calculated for C16H14BrNO: C 60.76, H 4.47, N 4.43% Analysis Calculated for C16H14BrNO: C 60.76, H 4.47, N 4.43% ES MS (+): m/z 272.0 [MH+]
7.22 (br. dd, 1H, CH, 3$(1H-1H) = 9.0$ Hz), 5.95 (s, CH, methine CH), 2.17 (s, 3H, aliphatic CH3) 13C{1H} NMR (CDCl3, 125.9 MHz, 300.0 K) δ 118.1 (Q), 164.8 (d, Q, C-F, $J^{13C-19F} = 250.5$ Hz), 161.5 (Q), 158.3 (d, Q, C-F, $J^{13C-19F} = 242.3$ Hz), 157.2 (Q), 137.5 (Q), 129.6 (2 x CH), 128.2 (d, CH, 3$(1H-1H) = 2.2$ Hz), 127.9 (dd, Q, C-F, $J^{13C-19F} = 24.7$ Hz and $J^{13C-19F} = 21.7$ Hz), 113.1 (d, CH, 3$(1H-1H) = 21.7$ Hz), 115.3 (d, 3 x CH, CH(CH3)2), 105.6 (CH(CH3)2, 3$(1H-1H) = 7.0$ Hz), 2.03 (s, 3H, methyl CH3), 1.74 (s, 3H, aliphatic CH3), 1.28 (d, 3H, CH(CH3)2, 3$(1H-1H) = 6.8$ Hz), 5.06 (br. d, br. d, CH, CH, 3$(1H-1H) = 6.0$ Hz), 5.16 (br. d, br. d, CH, CH, 3$(1H-1H) = 6.0$ Hz), 5.06 (br. d, br. d, CH, CH, 3$(1H-1H) = 5.6$ Hz), 3.68 (br. d, br. d, CH, CH, CH(CH3)2), 1.41 (d, 3H, CH(CH3)2, 3$(1H-1H) = 9.0$ Hz), 9.11 (1H, CH(CH3)2), CH(CH3)2), 1.41 (d, 3H, CH(CH3)2, 3$(1H-1H) = 9.0$ Hz), 1.41 (d, 3H, CH(CH3)2, 3$(1H-1H) = 9.0$ Hz).
Complex 6 (0.06 g, 0.10 mmol, 60%)

'H NMR (CDCl₃, 300.13 MHz, 300.0 K) δ 7.75 (dd, 1H, CH, δ (H'–H) = 7.3 Hz, δ (H'H) = 1.6 Hz), 7.45 (br. t, 2H, CH, δ (H'–H) = 6.5 Hz), 7.34 (d, 1H, CH, δ (H'–H) = 8.3 Hz), 7.27–7.22 (m, 2H, CH), 7.14–7.09 (m, 1H, CH), 5.27 (br. d, 1H, CH, δ (H'–H) = 6.2 Hz), 5.12 (br. d, 1H, CH, δ (H'H) = 6.2 Hz), 5.03 (br. d, 1H, CH, δ (H'–H) = 6.8 Hz), 4.88 (s, 1H, methine CH), 3.63 (br. d, 1H, CH, δ (H'–H) = 5.7 Hz), 2.76 (br. sept, 1H, CH(CH₃)₂), 1.97 (s, 3H, aliphatic CH₃), 1.84 (s, 3H, aliphatic CH₃), 1.60 (s, 3H, methyl CH₃), 1.10 (s, 3H, methyl CH₃).

13C{1H} NMR (CDCl₃, 75.5 MHz, 300.6 K) δ 171.7 (CH), 83.8 (CH), 83.7 (CH), 80.4 (CH), 30.3 (CH(CH₃)₂), 24.3 (aliphatic CH), 23.6 (CH(CH₃)₂), 21.4 (CH(CH₃)₂), 18.6 (methylyl CH₃) Analysis Calculated for C₂₆H₂₅BrClINORu: C 53.16, H 4.15, N 2.29, Cl 23.23% Analysis Found for C₂₆H₂₅BrClINORu: C 53.40, H 4.30, N 2.26%, Cl 23.18% ES Found Analysis for C₂₆H₂₅BrClINORu: C 53.40, H 4.30, N 2.26%, Cl 23.18%

Complex 7 (0.31 g, 0.54 mmol, 71%)

'H NMR (CDCl₃, 500.23 MHz, 300.0 K) δ 8.00 (br. t, 1H, CH, δ (H'–H) = 1.6 Hz), 7.76–7.73 (br. d, 2H, CH, δ (H'–H) = 8.0 Hz), 7.48 (br. d, 1H, CH, δ (H'–H) = 7.6 Hz), 7.43 (br. d, 1H, CH, δ (H'–H) = 7.5 Hz), 7.24 (br. t, 1H, CH, δ (H'–H) = 7.6 Hz), 7.20 (t, 1H, CH, δ (H'–H) = 7.9 Hz), 7.09 (d, 1H, CH, δ (H'–H) = 6.4 Hz), 5.38 (s, 1H, methine CH), 5.35 (br. d, 1H, CH, δ (H'–H) = 7.6 Hz), 5.07 (br. d, 1H, CH, δ (H'–H) = 6.0 Hz), 5.07 (br. d, 1H, CH, δ (H'–H) = 5.6 Hz), 3.69 (br. d, 1H, CH, δ (H'–H) = 6.6 Hz), 2.69 (br. sept, 1H, CH(CH₃)₂), 2.03 (s, 3H, methyl CH₃), 1.79 (s, 3H, aliphatic CH₃), 1.22 (s, 3H, CH(CH₃)₂), (δ (H'–H) = 7.1 Hz), 1.20 (d, 3H, CH(CH₃)₂), (δ (H'–H) = 7.1 Hz) Analysis Found for C₂₆H₂₇BrClINORu: C 51.50, H 4.15, N 2.20%, Cl 23.20% ES MS (+): m/z 574.04 [M⁺]–Cl

Complex 8 (0.19 g, 0.33 mmol, 66%)

'H NMR (CDCl₃, 300 MHz, 300 K) δ 7.85 (d, 3H, CH, δ (H'–H) = 7.6 Hz), 7.23 (s, 1H, CH, δ (H'–H) = 7.4 Hz), 7.09 (s, 1H, CH, δ (H'–H) = 6.4 Hz), 5.35 (s, 1H, methine CH), 5.35 (br. d, 1H, CH, δ (H'–H) = 6.2 Hz), 5.12 (br. d, 1H, CH, δ (H'–H) = 6.0 Hz), 5.07 (br. d, 1H, CH, δ (H'–H) = 5.7 Hz), 2.66 (br. sept, 1H, CH(CH₃)₂), (δ (H'–H) = 6.9 Hz), 2.02 (s, 3H, methyl CH₃), 1.79 (s, 3H, aliphatic CH₃), 1.20 (s, 6H, CH₂(CH₃)₂), (δ (H'–H) = 6.3 Hz) Analysis Found for C₂₆H₂ₙBrClINORu: C 51.50, H 4.15, N 2.20%, Cl 23.20% ES MS (+): m/z 552.03 [M⁺]–Cl

Complex 9 (0.16 g, 0.25 mmol, 62%)

'H NMR (CDCl₃, 300 MHz, 300 K) δ 7.74 (d, 2H, 2CH, δ (H'–H) = 8.3 Hz), 7.49–7.44 (m, 3H, 3CH), 7.42 (br. d, 1H, CH, δ (H'–H) = 7.6 Hz), 7.23 (s, 1H, CH, δ (H'–H) = 7.4 Hz), 7.09 (br. d, 1H, CH, δ (H'–H) = 6.4 Hz), 5.39 (s, 1H, methine CH), 5.35 (br. d, 1H, CH, δ (H'–H) = 6.2 Hz), 5.16 (br. d, 1H, CH, δ (H'–H) = 6.2 Hz), 5.07 (br. d, 1H, CH, δ (H'–H) = 5.3 Hz), 3.68 (br. d, 1H, CH, δ (H'–H) = 5.7 Hz), 2.66 (br. sept, 1H, CH(CH₃)₂), (δ (H'–H) = 6.0 Hz), 2.02 (s, 3H, methyl CH₃), 1.79 (s, 3H, aliphatic CH₃), 1.24–1.16 (m, 6H, CH₂(CH₃)₂) Analysis Found for C₂₆H₂ₙBrClINORu: C 52.90, H 4.60, N 2.35% Analysis Found for C₂₆H₂ₙBrClINORu: C 52.90, H 4.60, N 2.35% ES MS (+): m/z 516.15 [M⁺]–Cl

Complex 10 (0.16 g, 0.29 mmol, 68%)

'H NMR (CDCl₃, 500.57 MHz, 300.7 K) δ 7.82 (br. d, 2H, CH, δ (H'–H) = 8.7 Hz), 7.67 (br. d, 1H, CH, δ (H'–H) = 8.2 Hz), 7.42 (br. t, 2H, CH, δ (H'–H) = 7.6 Hz), 7.25–7.20 (m, 3H, CH), 7.10 (br. d, 1H, CH, δ (H'–H) = 7.4 Hz), 6.84 (br. d, 2H, CH, δ (H'–H) = 8.7 Hz), 5.39 (s, 1H, methine CH), 5.34 (br. d, 1H, CH, δ (H'–H) = 5.0 Hz), 5.16 (br. d, 1H, CH, δ (H'–H) = 6.0 Hz), 5.06 (br. d, 1H, CH, δ (H'–H) = 5.0 Hz), 2.68 (br. sept, 1H, CH(CH₃)₂), (δ (H'–H) = 7.4 Hz), 2.03 (s, 3H, methyl CH₃), 1.78 (s, 3H, aliphatic CH₃), 1.43 (t, 3H, ethoxy CH₃), (δ (H'–H) = 6.9 Hz), 1.24–1.16 (t, 6H, CH₂(CH₃)₂), (δ (H'–H) = 6.9 Hz) Analysis Found for C₂₆H₂ₙClINORu: C 61.03, H 5.85, N 2.54, Cl 6.43% Analysis Found for C₂₆H₂ₙClINORu: C 59.65, H 5.85, N 2.35, Cl 1/m% ES MS (+): m/z 516.15 [M⁺]–Cl
Complex 17 (0.06 g, 0.06 mmol, 46%) Complex 17 was synthesised according to the previous ruthenium complex preparation, with addition of 2 equivalents of NH-β-ketoiminate ligand.

**1H NMR (CDCl₃, 300 MHz, 300 K)** δ 7.87-7.8 (m, 1H, 3 x CH), 7.53-7.57 (m, 2H, 3 x CH), 7.45-7.4 (m, 2H, 3 x CH), 5.72 (d, 2H, 3 x CH), 2.85 (br. sept, 1H, 3 x CH(CH₃)₂), 1.35 (br. m, 6H, 3 x CH(CH₃)₂) / Complex 18 (0.07 g, 0.13 mmol, 58%) Complex 18 was synthesised by addition of [Cp*IrCl₂] (1 eq), a 3-fluoro-β-diketonate ligand (2 eq) and Et₃N (2 eq). All were stirred in dichloromethane (30 mL) at room temperature overnight. The solvent removed under reduced pressure and the crude product recrystallised using slow evaporation from a methanolic solution.

**1H NMR (CDCl₃, 300 MHz, 299.2 K)** δ 7.66-7.61 (m, 1H, 3 x CH), 7.67-7.54 (m, 1H, 3 x CH), 7.37-7.28 (m, 1H, 3 x CH), 7.19-7.10 (m, 1H, 3 x CH), 5.85 (s, 1H, methine CH), 2.08 (s, 3H, 3 x CH₃), 1.66 (br. s, 15H, Cp * methyl C(CH₃)) / **Cell Line Chemosensitivity Studies** In *vitro* chemosensitivity tests were performed at the Institute of Cancer Therapeutics, Bradford, against MCF-7 (human breast adenocarcinoma), HT-29 (human colon adenocarcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant A2780 cells) cell lines. Growth inhibitory effects were also tested against ARPE-19 cells. ARPE-19 are a human retinal epithelial non-cancer cell line that was obtained from the American Type Culture Collection. Cancer cell lines were routinely maintained as monolayer cultures in appropriate medium (RPMI 1640 supplemented with 10% foetal calf serum, sodium pyruvate (1 mM) and L-glutamine (2 mM) AREP-19 cells were cultured in DMEM-F12 medium containing 10% foetal calf serum. For chemosensitivity studies, cells were incubated in 96-well plates at a concentration of 2 x 10⁵ cells per well and the plates were incubated for 24 hours at 37 °C in an atmosphere of 5% CO₂. Drug solutions were added to cells (the final DMSO concentrations was less than 0.1% v/v) in all cases and incubated for 5 days at 37 °C in an atmosphere of 5% CO₂. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (20 µL, 5 mg mL⁻¹) was added to each well and incubated for 3 hours at 37 °C in an atmosphere of 5% CO₂. All solutions were then removed via pipette and 150 µL
of dimethylsulfoxide added to each well in order to dissolve the purple formazan crystals. A Thermo Scientific Multiskan EX microplate photometer was used to measure the absorbance of each well at 540 nm. Lanes containing medium only and 100% cells were used as blanks for the spectrophotometer and 100% cell survival respectively. Cell survival was determined as the absorbance of treated cells divided by the absorbance of controls and expressed as a percentage. The IC\textsubscript{50} values were determined from plots of % survival against drug concentration. Each experiment was repeated three times and a mean value obtained and stated as IC\textsubscript{50} (μM) ± SD. To quantify the response of tumour cells compared to normal cells, IC\textsubscript{50} values were expressed as the ratio of IC\textsubscript{50} in ARPE-19 cells divided by the IC\textsubscript{50} for individual tumour cells evaluated. A ratio of greater than 1 indicates selectivity towards cancer cells. IC\textsubscript{50} values (μM) and the standard deviations (SD) after a minimum of three repeats are presented in Table S3a and S3b (see SI).

**Influence of Hypoxia**

The hypoxia assay was conducted according to the protocol stated previously for normoxic conditions. However, the incubation period, the addition of the drug dilutions and the addition of the MTT solution were carried out inside a Don Whitley Scientific H35 Hypoxystation which was set at 1.0 or 0.1% O\textsubscript{2}. Cisplatin was tested as a comparison and a well-known hypoxic sensitive compound tirapazamine (TPZ) was tested as a positive control. These results are presented in Table S3a and S3b (see SI).

**Inhibition of thioredoxin reductase activity**

Thioredoxin reductase sourced from rat liver was obtained from Sigma Aldrich. It is a buffered aqueous glycerol solution, ≥ 100 units/ mg protein. Solution in 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM EDTA, and 10% glycerol. The rate of change of UV-vis absorbance was measured at 412 nm over 1 min to give the reaction velocity. The experiment was carried out using just the enzyme to get the control (no inhibitor) reaction velocity and then varying dilutions of the test compound were added up to a maximum of 10 μM. The reaction velocity in the presence of inhibitor was normalised relative to the control to generate % activity and plots of % activity versus concentration were constructed to obtain IC\textsubscript{50} values (concentration that inhibited 50% of enzyme activity). For full experimental and IC50 values cf. Figure S5 (see SI).

**Induction of Cancer Cell Death by Apoptosis**

Cells were incubated in T-25 flasks and diluted to concentrations of 2.5 x 10\textsuperscript{4} cells/flask (0.5 x 10\textsuperscript{4} cells/ mL) using complete RPMI 1640 medium. These were incubated for 24 hours at 37°C in an atmosphere of 5.0% CO\textsubscript{2}. Complexes were dissolved in dimethylsulfoxide and then further diluted with RPMI 1640 to obtain concentrations ranging from 20-0 μM. The cells were then incubated with the varying concentrations of complex for 48 hours, media/drug solutions were removed and flask were washed with PBS (5 mL), adding all washings to a centrifuge tube. Trypsin (1 mL/flask) was added to each flask and then incubated for 5 minutes until a single cell suspension was obtained. The trypsin was then neutralised with medium (5 mL) and the whole contents of the flask transferred to the same centrifuge tube. The tube was centrifuged at 1000 rcf for 3-5 minutes, the supernatant removed and the pellet re-suspended in PBS (1 mL). The 1 mL was transferred to an Eppendorf and centrifuged at 1500 rpm for 5 minutes. The supernatant was removed and the pellet re-suspended in 16 μL PI, 16 μL AmV and 800 μL buffer solution (100 μL). The Eppendorf’s were incubated at room temperature for 10 minutes and kept in suspension; and then transferred to FACS tubes for analysis. Samples were run using flow cytometry and parameters adjusted depending on the sample tested. A cell count of 10,000 was necessary to conduct this experiment and gave results of PI versus Annex V, each quadrant was analysed manually and a percentage taken from each quadrant of the plot, and values are presented in Table S8 (see SI).

**Analysis of cellular DNA damage by the comet assay**

Slides containing a layer of agarose were prepared in advance, using 1% normal melting point agarose (500 mg) in PBS (50 mL). The cells were diluted with complete RMPI 1640 to a concentration of 1 x 10\textsuperscript{5} cells/ mL, 2 mL of the cell suspension was placed in each well of a 6-well plate. The cells were incubated for 24 hours at 37°C in a 5.0% CO\textsubscript{2} atmosphere. Drug samples were prepared in the range 20-0 μM, the medium was removed from the wells, and 2 mL of drug sample added to each well. The plate was then incubated again for 24 hours in the drug solutions, at 37°C in a 5.0% CO\textsubscript{2} atmosphere. The drug samples were removed and added to centrifuge tubes, the wells each washed with PBS (1 mL), which was also placed into the centrifuge tube. The wells were then trypsinised (1 mL) for 5 minutes and then neutralised with complete medium (1 mL), these were all added to the centrifuge tube and centrifuged at 1500 rpm for 3 minutes. The supernatant was removed and the pellet re-suspended in complete medium containing 10% DMSO (no not use DMSO with single strand assay). The tubes were wrapped in several sheets of tissue and stored at -80°C until required for the assay. When conducting the cross-linking assay, the same protocol is followed with an additional step of exposing the cells to 10% H\textsubscript{2}O\textsubscript{2} for 20 minutes before harvesting the cells. For reagents, conditions and graphically analysis see Figure S4-6 (SI).

**Supporting Information:** Crystallographic data and selected bond lengths and angles for ligands 1-3, 6, 8 and 11, and complexes 2, 4-14, 17 and 18. Additional assays on hydrophobicity and hydrolysis. IC\textsubscript{50} figures and tables for normoxic (HT-29, MCF-7, A2780, A2780cis and ARPE-19) and hypoxic assays (HT-29). Chemicals, experimental and data curves for thioredoxin reductase assay. Cell viability (%) for apoptosis studies (HT-29 and A2780), chemicals and experimental. Comet assay chemicals, experimental and bar-charts, with selected microscope images. This material is available free of charge via the Internet at http://pubs.acs.org.
ACKNOWLEDGMENT

We would like to thank the EPSRC for funding and all the technical staff at the University of Leeds for help with NMR (Mr Simon Barrett), mass spectrometry (Ms. Tanya Marinko-Covell) and microanalysis (Mr. Ian Blakeley).

ABBREVIATIONS

REFERENCES